Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Disclosed herein are methods for generating SC-β cells using chemically defined, completely serum free media, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

A method for obtaining a fraction of a fetal cell culture supernatant, including the steps of obtaining a cell-containing sample of tissue (such as cartilage) or (cord-)blood or bone marrow from a non-human mammalian fetus, culturing the sample in a liquid cell culture medium, thereby obtaining a cell culture with a liquid supernatant, and isolating a fraction from the supernatant. Furthermore, a fraction obtainable by this method is provided. A pharmaceutical composition including this fraction is also provided, preferably for use in therapy, such as for use in a prevention or treatment of osteoarthritis, arthritis, tendinitis, tendinopathy, cartilage injury, tendon injury, rheumatoid arthritis, discospondylitis, meniscus injury, desmitis, desmopathy, intervertebral disc injuries, degenerative disease of intervertebral discs, reperfusion injury, wounds or inflammatory disease.

Directed differentiation and maturation of mammalian hepatocytes, such as human hepatocytes. The hepatocyte obtained show a phenotype which is more similar to that of primary hepatocytes than previously shown. In particular, exposure of mammalian hepatocytes, such as human hepatocytes, to at least one maturation factor selected from the group consisting of Src kinase inhibitors, vitamin D including precursors, metabolites and analogs thereof, hypoxia inducing compounds, sphingosine and sphingosine derivatives, activators of peroxisome proliferator-activated receptors (PPARs), platelet-activating factor (PAF), PKC inhibitors, and combinations thereof.

A method for producing cell aggregates includes culturing cells while suspending the cells in a liquid culture medium comprising a lysophospholipid. A composition includes a lysophospholipid, wherein the composition is a liquid culture medium or a composition added to a liquid culture medium.

Provided herein are, inter alia, methods for preparing a liquid cell culture media that has lesser lot-to-lot analytical variation, increased performance, and has lesser metal ion concentrations compared to a liquid media prepared by traditional methods. Such liquid media may be used for culturing cells, including but not limited to, recombinant cells.

Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.

An improved cryopreservation process and substances can involve a cellular collection (1) in a cryopreservation fluid (4) that has been conditioned or treated (7) to enhance the cryopreservation process by adding (18) energy (19) such as in the surface energy of a substance in the cryopreservation fluid (4) prior to reducing energy for that same cryopreservation media for freezing. This can offer enhanced-post-cryogenic viability of the cryopreserved structures or a more optimum cooling curve (22) for a specific cell type.

The present disclosure describes a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a cell product comprising an expanded and enriched population of superactivated cytokine killer T cells, and methods for manufacturing the cell product.

The present disclosure provides materials and methods for the treatment of autoimmune diseases (including vitiligo).